News
Senti Bio gets additional $1.0 million tranche from CIRM grant for advancing clinical development of SENTI-202: South San Francisco, California Friday, May 23, 2025, 16:00 Hrs [IS ...
2d
Zacks.com on MSNACMR vs. AMAT: Which Semiconductor Equipment Stock Has the Edge?As China boosts domestic fabs, ACMR gains ground. AMAT leads in AI chip tech. Both face new challenges as steep tariffs ...
Discrete Semiconductor Market growth is driven by rising demand for power-efficient devices, EV adoption, and advancements in consumer electronics an ...
Q2 2025 Earnings Call Transcript May 15, 2025 Applied Materials, Inc. beats earnings expectations. Reported EPS is $2.39, ...
Data does not lie. According to market research, within 30 days from suspension to resumption of trading, successful ...
4dOpinion
The New Republic on MSNMAGA Loses It as Trump Officials Say Jeffrey Epstein Killed HimselfOn Sunday, Fox News’s Maria Bartiromo grilled FBI Director Kash Patel and his deputy director, Dan Bongino, over the ...
4dOpinion
The New Republic on MSNCBS News CEO Suddenly Quits as Network Considers Caving to TrumpWendy McMahon is the second high-profile executive to step down from the network amid an internal war over Trump’s lawsuit.
The EDA market segment and its product portfolio have a huge impact on the semiconductor industry. Without automation tools for chip/system design and verification, there ...
2d
Zacks Investment Research on MSNShould You Buy, Sell or Hold Nova Stock After a 28% Dip in 3 Months?Nova Ltd. NVMI shares have lost 27.9% in the past three months, underperforming the Zacks Electronics – Semiconductors ...
JEE Advanced 2025 is scheduled for May 18. Know the paper timings, dress code, items to carry, banned items, and last-minute ...
Chris Toomey, Morgan Stanley managing director of private wealth, said in a latest program on CNBC that he is not bullish on stocks yet and plans to “stay defensive” until a few key issues are ...
Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refracto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results